Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Other

Avalyn plots IPO to push inhaled pulmonary fibrosis pipeline through clinic

 April 9, 2026

BioSpace

Analysts are cautiously optimistic about an IPO rebound for biopharma.

OtherRespiratoryRead full story

Post navigation

Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb →
← Pulmonary fibrosis drug developer Avalyn files IPO

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com